Sep 25,2018

Big Health’s CBT app improves conditions of users with insomnia symptoms

A new dual-arm randomized trial published this morning in JAMA Psychiatry found that use of Big Health’s Sleepio app as a digital cognitive behavioral therapy (dCBT) led to significant improvements in self-reported functional health, psychological wellbeing, and sleep-related quality of life among those with symptoms to insomnia. Among a study group of 1,711 users, use of the Sleepio app appeared to drive improvements in self-reported functional health, psychological wellbeing, and sleep-related quality of life.

CLINICAL STUDY

#mobile app

#cbt

View Analyst & Ambassador Comments
Go to original news
Nov 15,2018

Theranica Announces Results from Pivotal Study of Device for Treating Acute Migraine

The prospective, randomized, double-blind, sham-controlled, multi-center study evaluated the efficacy, safety and tolerability of the device on 252 patients who met the International Classification of Headache Disorders (ICHD-3) criteria of migraine with or without aura. The study met its primary and almost all of its secondary and exploratory results with high statistical significance. On its primary endpoint of pain relief at 2 hours post-treatment the device demonstrated 66.7% response rate in the active arm vs. 38.8% in the placebo.

CLINICAL STUDY

#pdt

#connected device

#mobile app

View Analyst & Ambassador Comments
Go to original news
Dec 03,2018

Impact of a digital health intervention on asthma resource utilization

This quality improvement project assessed the benefit of these interventions (Propeller Health) on asthma-related healthcare utilizations, including hospitalizations, emergency department (ED) utilization and outpatient visits. In 224 study patients, the number of asthma-related ED visits and combined ED and hospitalization events 365 days pre- to 365 days post-enrollment to the intervention significantly decreased from 11.6 to 5.4 visits (p < 0.05) and 13.4 to 5.8 events (p < 0.05) per 100 patient-years, respectively. This digital health intervention was successfully incorporated into routine clinical practice and was associated with lower rates of asthma-related hospitalizations and ED visits.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Nov 13,2018

Omada Program for Underserved Participants Delivers Strong Results

Today, researchers from the University of Southern California presented the results of a clinical study on the effectiveness of Omada’s Digital Diabetes Prevention Program with low-income, underserved populations. Revealed at the American Public Health Association (APHA) Annual Meeting, the results of a clinical trial demonstrated the Omada Program delivered greater than four percent weight loss at the end of the trial period. Nearly 40 percent of participants lost at least five percent of their starting body weight. The program also saw strong engagement early, with 55 percent of users completing a minimum of nine of the initial 16 lessons.

CLINICAL STUDY

#coaching

#connected device

View Analyst & Ambassador Comments
Go to original news
Mar 01,2018

Patient experience, efficiency and cost effects of digital patient monitoring evaluated at the new study by Helsinki University Hospital

Urology department of Helsinki University Hospital has started a new research project ePRO-PCaRP/RT* evaluating patient experience, efficiency and cost effects of digital patient monitoring among prostate cancer patients. Kaiku Health application and an electronic questionnaire is used to evaluate the patient’s quality of life. Over 600 prostate cancer patients treated with both surgery and radiotherapy will be invited to participate in the research. Duration of this randomized phase III trial is approximately two years and the results will be published in relevant scientific journals

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Feb 07,2018

Virta Health’s Treatment for Sustained Type 2 Diabetes Reversal Provides New Hope for Chronic Disease Patients

Virta Health, the first company with a clinically-proven treatment to safely and sustainably reverse type 2 diabetes and other chronic metabolic diseases without the use of medications or surgery, today announced the peer-reviewed publication of 1-year results from its ongoing clinical trial, now 2.5 years in duration. The study augments Virta Health’s existing body of peer-reviewed research, which proved that the Virta Treatment could systematically reverse type 2 diabetes in as little as 10 weeks. Newly released data demonstrates that diabetes reversal rates are sustained and in fact improved at one year, while metrics of other chronic conditions, such as obesity, blood pressure, cardiovascular disease and inflammation, are also substantially improved.

CLINICAL STUDY

#virtual care

View Analyst & Ambassador Comments
Go to original news
May 02,2018

Virta Health Changing Status Quo in Chronic Disease Care with Strong Cardiovascular Outcomes from Type 2 Diabetes Reversal Study

Virta Health, the first company with a clinically-proven treatment to safely and sustainably reverse type 2 diabetes (T2D) and other chronic metabolic diseases without the use of medications or surgery, today announced the publication of new peer-reviewed research in Cardiovascular Diabetology on the cardiovascular benefits of the Virta Treatment. For trial participants living with T2D, the Virta Treatment demonstrated statistically significant improvements in 22 of 26 markers of cardiovascular disease risk, including blood pressure, while reducing dependence on blood pressure medications. In contrast, those following their usual T2D care experienced no significant improvement in any of the same 26 parameters.

CLINICAL STUDY

#virtual care

View Analyst & Ambassador Comments
Go to original news
Nov 29,2017

A1C Improvement for People with Diabetes is Possible!

A study published in JMIR mHealth & uHealth found people with diabetes using the One Drop | Mobile app on their iPhone and Apple Watch reduce their hemoglobin A1c by an average 1.36%. Without the Apple Watch, the estimated A1c improvement is 1% in three months.

CLINICAL STUDY

#mobile app

#connected device

View Analyst & Ambassador Comments
Go to original news
Dec 04,2017

Akili Achieves Primary Efficacy Endpoint in Pediatric ADHD Pivotal Trial

Akili Interactive announced top-line results from the Company’s STARS-ADHD pivotal study of its lead investigational digital medicine, AKL-T01, in ADHD. In a randomized, controlled trial of 348 children and adolescents diagnosed with ADHD, AKL-T01 showed a statistically significant improvement compared to an active control on the predefined primary endpoint, a change in the Attention Performance Index.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jan 24,2017

Outcomes of a Digital Health Program With Human Coaching for Diabetes Risk Reduction in a Medicare Population

The aim of the study is to examine the outcomes of a Medicare population who participated in a program combining digital health with human coaching for diabetes risk reduction. People at risk for diabetes enrolled in a program (Omada Health) combining digital health with human coaching. Participation and health outcomes were examined at 16 weeks and 6 and 12 months. A total of 501 participants were enrolled. This Medicare population demonstrated sustained program engagement and improved weight, health, and well-being. The findings support digital programs with human coaching for reducing chronic disease risk among older adults.

CLINICAL STUDY

#mobile app

#coaching

View Analyst & Ambassador Comments
Go to original news
Subscribe to CLINICAL STUDY